News | May 12, 2015

SCAI 2015 Case Studies Will Support Value of Accrediation for Cardiovascular Excellence Credentials

ACE cath/PCI labs continually meet highest standards in quality, performance and outcome measures

ACE, accreditation, cath lab, PCI, SCAI 2015, case studies

May 13, 2015 — For the first time, cardiac catheterization laboratory stakeholders now have quality metrics that confirm the value of Accreditation for Cardiovascular Excellence (ACE) accreditation. Three new studies validating the benefits of ACE accreditation were presented during the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in San Diego, California, May 6-9.

In the series of studies, Bonnie H. Weiner, M.D., MSEC, MBA, MSCAI, FACC, and colleagues examined multiple quality, performance and outcome measures among 24 facilities that have achieved full ACE accreditation for their diagnostic cardiac catheterization and percutaneous coronary intervention (cath/PCI) programs; the group also studied four facilities that did not meet the rigorous standards for ACE accreditation.

"We found that ACE-accredited cardiac catheterization laboratories were significantly more likely than non-accredited facilities to meet the highest-quality standards for more than a dozen structural, process-related and procedural domains," said Weiner, ACE's chief medical officer. "These data clarify and support the critical role of ACE accreditation in assisting facilities to provide excellent cardiovascular care."

The studies focused on structural and process domains (Abstract 13849) and case-level procedural characteristics (Abstract 13862) that significantly differentiated ACE-accredited cardiac catheterization laboratories from facilities that did not achieve accreditation. Additional survey data highlighted the perceived value of undergoing the ACE external review and accreditation and process (Abstract 13833).

"More than 90 percent of ACE-accredited facilities feel that accreditation adds substantial value to their organization in terms of improved care quality," Weiner said. "The value proposition of ACE accreditation touches every aspect of the cardiac catheterization laboratory, from enhanced patient safety to improved staff confidence and morale."

Data Presented
Performance on multiple outcomes measures differed significantly between cardiac catheterization laboratories that achieved accreditation through ACE and those that did not initially achieve accreditation, according to fthe data. Overall, outcomes on 11 measures related to appropriate use criteria (AUC), procedural findings, and other metrics were significantly different between invasive cardiac cases performed at accredited versus non-accredited facilities.

To identify potential performance differences between facility types, the investigators compared case data from 1,445 patients undergoing invasive cardiac procedures at 20 ACE-accredited facilities to data from 445 patients treated at 4 facilities that did not meet the rigorous standards for ACE accreditation. All case review data were entered into a uniform case report form and analyzed with standard statistical software (JMP 11.2.0).
 
"We found statistically significant differences across multiple performance domains that distinguish the invasive procedures performed at ACE-accredited cardiac catheterization laboratories from those performed at non-accredited facilities," Weiner said. "These findings demonstrate that ACE-accredited facilities are delivering quality cardiac care that is more likely to be consistent with national standards of cardiovascular excellence."
 
The invasive procedures performed at ACE-accredited facilities were more likely than those at non-accredited facilities to be characterized by diagnostic AUC scored as appropriate (74.1% vs. 57.7%; p<0.0001), adequate opacification (93.1% vs. 82.0%; p<0.0001), and adequate lesion characterization (91.3% vs. 83.8%; p<0.0001).
 
Standardizing the documentation and reporting of key procedural details is critically important for demonstrating appropriate use and medical necessity. Overall case assessments were significantly more likely to be deemed appropriate for the invasive cardiac procedures performed at ACE-accredited facilities compared with those performed at non-accredited facilities (73.6 vs. 63.1%; p<0.0001).
 

For more information: www.cvexcel.org

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init